Rani Therapeutics Inc. (RANI)
NASDAQ: RANI
· Real-Time Price · USD
0.62
-0.03 (-4.34%)
At close: May 23, 2025, 3:59 PM
0.62
0.00%
After-hours: May 23, 2025, 04:00 PM EDT
-4.34% (1D)
| Bid | 0.62 |
| Market Cap | 35.49M |
| Revenue (ttm) | 1.03M |
| Net Income (ttm) | -29.8M |
| EPS (ttm) | -0.98 |
| PE Ratio (ttm) | -0.63 |
| Forward PE | -0.83 |
| Analyst | Buy |
| Ask | 0.67 |
| Volume | 264,376 |
| Avg. Volume (20D) | 392,834 |
| Open | 0.63 |
| Previous Close | 0.65 |
| Day's Range | 0.62 - 0.66 |
| 52-Week Range | 0.46 - 5.74 |
| Beta | 0.25 |
About RANI
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RANI
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RANI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
+15.59%
Rani Therapeutics Holdings shares are trading high...
Unlock content with
Pro Subscription
3 months ago
+14.58%
Rani Therapeutics Holdings shares are trading higher after the company announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the glucagon-like peptide-1 receptor agonist semaglutide administered via the RaniPill capsule.
1 month ago · seekingalpha.com
Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call TranscriptRani Therapeutics Holdings, Inc. (NASDAQ:RANI ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Kiki Patel - IR, Gilmartin Group Talat Imran - CEO Svai Sanford - CFO Co...